Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but subgroup analyses suggested a benefit of oral insulin in individuals with the highest titres of insulin auto-antibodies.142,143”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“The Diabetes Prevention Trial—Type 1, tested whether oral or parental insulin prevented the development of type 1 diabetes in people who were autoantibody positive. Neither approach reduced diabetes development,”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“If one islet autoantibody is found, the test should be repeated and the other autoantibodies should be assayed because the risk of type 1 diabetes increases if two or more autoantibodies are positive (443).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [443]
In the citing paper
“Subcutaneously or intranasally delivered insulin was found to have no preventive effects.39,48”
From The future of type 1 diabetes therapy (2025) · cites this paper as [48]
In the citing paper
“Risk can be assessed by islet cell autoantibodies alone, without the need for evaluating endogenous insulin reserves, as was done for the U.S. DPT-1 trial (306).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [306]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Cognitive Deficits in Adolescents Who Developed Diabetes Early in Life
Ryan, C., Vega, A., & Drash, A. (1985) · Pediatrics · doi:10.1542/peds.75.5.921 · Cited by 413
Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy
Atkinson, M. A., Maclaren, N. K., & Luchetta, R. (1990) · Diabetes · doi:10.2337/diab.39.8.933 · Cited by 299
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Pugliese, A., Gianani, R., Moromisato, R., Awdeh, Z. L., Alper, C. A., Erlich, H. A., Jackson, R. A., & Eisenbarth, G. S. (1995) · Diabetes · doi:10.2337/diab.44.6.608 · Cited by 207
Gotfredsen, C. F., Buschard, K., & Frandsen, E. K. (1985) · Diabetologia · doi:10.1007/bf00703140 · Cited by 205
Vardi, P., Dib, S. A., Tuttleman, M., Connelly, J. E., Grinbergs, M., Radizabeh, A., Riley, W. J., Maclaren, N. K., Eisenbarth, G. S., & Soeldner, J. S. (1987) · Diabetes · doi:10.2337/diab.36.11.1286 · Cited by 192
Attentional Functioning in Children and Adolescents With IDDM
Rovet, J., & Alvarez, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.803 · Cited by 153
Cited by
Items 101–200 of 832
Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine
Roep, B. O., Wheeler, D. C. S., & Peakman, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30109-8 · Cited by 133
Recent advances in mucosal vaccines and adjuvants
Eriksson, K., & Holmgren, J. R. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00384-9 · Cited by 124
Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Yu, L., Mahon, J., Beam, C. A., Boulware, D. C., Rafkin, L., Schatz, D., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0425 · Cited by 123
Type 1 diabetes: A predictable disease
Simmons, K. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.380 · Cited by 117
Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network
Skyler, J. S., Greenbaum, C. J., Lachin, J. M., Leschek, E., Rafkin‐Mervis, L., Savage, P., Spain, L., & the Type 1 Diabetes TrialNet Study Group (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.054 · Cited by 118
Long-Term Outcome of Individuals Treated With Oral Insulin
Vehik, K., Cuthbertson, D., Ruhlig, H., Schatz, D. A., Peakman, M., Krischer, J. P., & Groups, F. T. D.-1. A. T. S. (2011) · Diabetes Care · doi:10.2337/dc11-0523 · Cited by 117
Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities
Torres, J., Burisch, J. M., Riddle, M. S., Dubinsky, M. C., & Colombel, J. (2016) · Gut · doi:10.1136/gutjnl-2016-311785 · Cited by 124
The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group, Bingley, P. J., & Gale, E. A. M. (2006) · Diabetologia · doi:10.1007/s00125-006-0160-4 · Cited by 121
Genetic epidemiology of type 1 diabetes: Genetic epidemiology of type 1 diabetes
Hirschhorn, J. N. (2003) · Pediatric Diabetes · doi:10.1034/j.1399-5448.2001.00013.x · Cited by 114
Wang, X., Jia, S., Geoffrey, R., Alemzadeh, R., Ghosh, S., & Hessner, M. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1929 · Cited by 110
Schloot, N. C., Meierhoff, G., Lengyel, C., Vándorfi, G., Takács, J., Pánczél, P., Barkai, L., Madácsy, L., Oroszlán, T., Kovács, P., et al. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.707 · Cited by 110
Immune therapy in type 1 diabetes mellitus
Lernmark, Å., & Larsson, H. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.237 · Cited by 111
Eisenbarth, G. S. (2010) · Diabetes · doi:10.2337/db09-1855 · Cited by 106
Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR)
The TRIGR Study Group* (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00239.x · Cited by 109
Yu, L., Boulware, D. C., Beam, C. A., Hutton, J. C., Wenzlau, J. M., Greenbaum, C. J., Bingley, P. J., Krischer, J. P., Sosenko, J. M., Skyler, J. S., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2081 · Cited by 104
Sosenko, J. M., Krischer, J. P., Palmer, J. P., Mahon, J., Cowie, C., Greenbaum, C. J., Cuthbertson, D., Lachin, J. M., Skyler, J. S., & the Diabetes Prevention Trial–Type 1 Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1459 · Cited by 105
Standardization of C-peptide measurements
Little, R. R., Rohlfing, C. L., Tennill, A. L., Madsen, R. W., Polonsky, K. S., Myers, G. L., Greenbaum, C. J., Palmer, J. P., Rogatsky, E., & Stein, D. T. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101287 · Cited by 103
Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?
Chatenoud, L. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.275 · Cited by 114
The rise and fall of insulin secretion in type 1 diabetes mellitus
for the DPT-1 Study Group, Tsai, E. B., Sherry, N., Palmer, J. P., & Herold, K. C. (2006) · Diabetologia · doi:10.1007/s00125-005-0100-8 · Cited by 110
Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data
Brown, R. J., & Rother, K. I. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00272.x · Cited by 104
von Herrath, M. G., & Nepom, G. T. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051224 · Cited by 101
Latent Autoimmune Diabetes in Adults (LADA)
Naik, R. G., & Palmer, J. P. (2003) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1025148211587 · Cited by 114
Role of immune system in type 1 diabetes mellitus pathogenesis
Szablewski, L. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.06.033 · Cited by 128
Changing the landscape for type 1 diabetes: the first step to prevention
Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32127-0 · Cited by 96
Classification and Diagnosis of Diabetes
GENUTH, S. M., Palmer, J. P., & Nathan, D. M. (2018) · Cited by 112
IA-2 autoantibodies predict impending Type I diabetes in siblings of patients
Decochez, K., Leeuw, I. D., Keymeulen, B., Mathieu, C., Rottiers, R., Weets, I., Vandemeulebroucke, E., Truyen, I., Kaufman, L., Schuit, F. C., et al. (2002) · Diabetologia · doi:10.1007/s00125-002-0949-8 · Cited by 106
Human islet T cells are highly reactive to preproinsulin in type 1 diabetes
Anderson, A. M., Landry, L. G., Alkanani, A. K., Pyle, L. L., Powers, A. C., Atkinson, M. A., Mathews, C. E., Roep, B. O., Michels, A. W., & Nakayama, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107208118 · Cited by 102
Wherrett, D. K., Chiang, J. L., Delamater, A. M., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lovell, D. J., Orchard, T. J., Ryan, C. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1429 · Cited by 93
Primary and secondary prevention of Type 1 diabetes
Skyler, J. S. (2013) · Diabetic Medicine · doi:10.1111/dme.12100 · Cited by 93
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 106
Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes
Turvey, S. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25048 · Cited by 94
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities
Skyler, J. S. (2015) · Diabetes Care · doi:10.2337/dc15-0349 · Cited by 85
The Stages of Type 1A Diabetes
BABAYA, N., NAKAYAMA, M., & EISENBARTH, G. S. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.061 · Cited by 90
Yu, H., Gagliani, N., Ishigame, H., Huber, S., Zhu, S., Esplugues, E., Herold, K. C., Li, W., & Flavell, R. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705599114 · Cited by 93
Environmental Factors Associated With Type 1 Diabetes
Esposito, S., Toni, G., Tascini, G., Santi, E., Berioli, M. G., & Principi, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00592 · Cited by 106
Sosenko, J. M., Skyler, J. S., DiMeglio, L. A., Beam, C. A., Krischer, J. P., Greenbaum, C. J., Boulware, D., Rafkin, L. E., Matheson, D., Herold, K. C., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1813 · Cited by 86
Thinking bedside at the bench: the NOD mouse model of T1DM
Reed, J. C., & Herold, K. C. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.236 · Cited by 95
Sosenko, J. M., Skyler, J. S., Beam, C. A., Krischer, J. P., Greenbaum, C. J., Mahon, J., Rafkin, L. E., Matheson, D., Herold, K. C., Palmer, J. P., et al. (2013) · Diabetes · doi:10.2337/db13-0656 · Cited by 85
Bingley, P. J., Wherrett, D. K., Shultz, A., Rafkin, L. E., Atkinson, M. A., & Greenbaum, C. J. (2018) · Diabetes Care · doi:10.2337/dc17-0806 · Cited by 83
The Belgian Diabetes Registry, Truyen, I., Pauw, P. E. M. D., Jørgensen, P. N., Schravendijk, C. F. H. V., Ubani, O. C., Decochez, K., Vandemeulebroucke, E., Weets, I., Mao, R., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1959-0 · Cited by 92
Predicting and Preventing Autoimmunity, Myth or Reality?
Harel, M., & Shoenfeld, Y. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.031 · Cited by 92
Michels, A. W., Zhang, L., Khadra, A., Kushner, J. A., REDONDO, M. J., & Pietropaolo, M. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12299 · Cited by 93
Korean red ginseng (Panax ginseng) ameliorates type 1 diabetes and restores immune cell compartments
Hong, Y. J., Kim, N., Lee, K., Sonn, C. H., Lee, J. E., Kim, S. T., Baeg, I.-H., & Lee, K.-M. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.08.009 · Cited by 81
Immunotherapy for the Prevention and Treatment of Type 1 Diabetes
Rewers, M., & Gottlieb, P. A. (2009) · Diabetes Care · doi:10.2337/dc09-0374 · Cited by 85
Breakdown in Peripheral Tolerance in Type 1 Diabetes in Mice and Humans
Jeker, L. T., Bour-Jordan, H., & Bluestone, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007807 · Cited by 95
Lernmark, Å., & Alshiekh, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.15001-5 · Cited by 79
Phases of type 1 diabetes in children and adolescents
Couper, J., Haller, M. J., Ziegler, A., Knip, M., Ludvigsson, J., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12188 · Cited by 93
The role of beta-cell dysfunction in early type 1 diabetes
Sims, E. K., Mirmira, R. G., & Evans-Molina, C. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000548 · Cited by 77
Sosenko, J. M., Palmer, J. P., Rafkin-Mervis, L., Krischer, J. P., Cuthbertson, D., Matheson, D., & Skyler, J. S. (2008) · Diabetes Care · doi:10.2337/dc08-0935 · Cited by 78
Sosenko, J. M., Palmer, J. P., Rafkin-Mervis, L., Krischer, J. P., Cuthbertson, D., Mahon, J., Greenbaum, C. J., Cowie, C. C., Skyler, J. S., & the Diabetes Prevention Trial–Type 1 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2140 · Cited by 76
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
Mallone, R., Brezar, V., & Boîtard, C. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/513210 · Cited by 87
Bonifacio, E., Hummel, M., Walter, M., Schmid, S., & Ziegler, A.-G. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2695 · Cited by 76
Autoantibody markers for the diagnosis and prediction of type 1 diabetes
Wasserfall, C. H., & Atkinson, M. A. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.12.002 · Cited by 86
Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects
Skyler, J. S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100179 · Cited by 77
Progress in immune-based therapies for type 1 diabetes
von Herrath, M., Peakman, M., & Roep, B. O. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12085 · Cited by 79
Andersson, C., Vaziri-Sani, F., Delli, A., Lindblad, B., Carlsson, A., Forsander, G., Ludvigsson, J., Marcus, C., Samuelsson, U., Ivarsson, S., et al. (2013) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00916.x · Cited by 74
Prediction and prevention of Type 1 diabetes mellitus
Zhang, L., & Eisenbarth, G. S. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00102.x · Cited by 80
Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count
So, M., Speake, C., Steck, A. K., Lundgren, M., Colman, P. G., Palmer, J. P., Herold, K. C., & Greenbaum, C. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab013 · Cited by 80
Nakayama, M., McDaniel, K. A., Fitzgerald-Miller, L., Kiekhaefer, C. M., Snell‐Bergeon, J. K., Davidson, H. W., Rewers, M., Yu, L., Gottlieb, P. A., Kappler, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502967112 · Cited by 80
Age-Dependent Influences on the Origins of Autoimmune Diabetes
Leslie, R. D. G., & Castelli, M. D. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3033 · Cited by 73
Achenbach, P., Barker, J. M., & Bonifacio, E. E. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0017-y · Cited by 75
Label‐Free Glucose Sensing Using Chip‐Scale Mid‐Infrared Integrated Photonics
Lin, P. T., Lin, H. G., Han, Z., Jin, T., Millender, R., Kimerling, L. C., & Agarwal, A. (2016) · Advanced Optical Materials · doi:10.1002/adom.201600440 · Cited by 75
Biason‐Lauber, A., Boehm, B. O., Lang‐Muritano, M., Gauthier, B. R., Brun, T., Wollheim, C. B., & Schoenle, E. J. (2005) · Diabetologia · doi:10.1007/s00125-005-1723-5 · Cited by 69
Jamison, B. L., Neef, T., Goodspeed, A. E., Bradley, B., Baker, R. L., Miller, S. D., & HASKINS, K. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900127 · Cited by 72
Can we accurately predict the development of rheumatoid arthritis in the preclinical phase?
Majka, D. S., & Holers, V. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11224 · Cited by 68
Insulin resistance in early untreated rheumatoid arthritis patients
Shahin, D., Eltoraby, E., Mesbah, A., & Houssen, M. E. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.01.012 · Cited by 71
Update on Worldwide Efforts to Prevent Type 1 Diabetes
Skyler, J. S., & for the Type 1 Diabetes TrialNet Study Group (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.055 · Cited by 66
Beyond the Hormone: Insulin as an Autoimmune Target in Type 1 Diabetes
Brezar, V., Carel, J., Boîtard, C., & Mallone, R. (2011) · Endocrine Reviews · doi:10.1210/er.2011-0010 · Cited by 77
Boscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 80
Gale, E., & Inte, T. E. N. D. (2003) · Diabetologia · doi:10.1007/s00125-003-1033-8 · Cited by 69
Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases
Bluestone, J. A., & Bour-Jordan, H. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007542 · Cited by 66
Graham, M. L., & Schuurman, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.054 · Cited by 75
Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
Assfalg, R., Knoop, J., Hoffman, K. L., Pfirrmann, M., Zapardiel‐Gonzalo, J., Hofelich, A., Eugster, A., Weigelt, M., Matzke, C., Reinhardt, J., et al. (2021) · Diabetologia · doi:10.1007/s00125-020-05376-1 · Cited by 71
Oral Insulin Therapy to Prevent Progression of Immune‐Mediated (Type 1) Diabetes
ERGUN‐LONGMIRE, B., MARKER, J., ZEIDLER, A., RAPAPORT, R., RASKIN, P., BODE, B., SCHATZ, D., VARGAS, A., ROGERS, D., SCHWARTZ, S., et al. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1309.057 · Cited by 65
Sui, B., Hu, C., Zheng, C., Shuai, Y., He, X., Gao, P., Zhao, P., Li, M., Zhang, X., He, T., et al. (2017) · Theranostics · doi:10.7150/thno.18181 · Cited by 78
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes
Roep, B. O., & Peakman, M. (2010) · Nature reviews. Immunology · doi:10.1038/nri2705 · Cited by 63
Sosenko, J. M., Palmer, J. P., Rafkin, L. E., Krischer, J. P., Cuthbertson, D., Greenbaum, C. J., Eisenbarth, G., Skyler, J. S., & Diabetes Prevention Trial–Type 1 Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1770 · Cited by 62
Self-citationElding Larsson, H., Lundgren, M., Jonsdottir, B., Cuthbertson, D., Krischer, J., & for the DiAPREV‐IT Study Group (2018) · Pediatric Diabetes · doi:10.1111/pedi.12611 · Cited by 63
MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete
Mallone, R., & Nepom, G. T. (2004) · Clinical Immunology · doi:10.1016/j.clim.2003.11.004 · Cited by 71
New Reagents on the Horizon for Immune Tolerance
St. Clair, E. W., Turka, L. A., Saxon, A., Matthews, J. B., Sayegh, M. H., Eisenbarth, G. S., & Bluestone, J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145449 · Cited by 62
Delli, A. J., Larsson, H. E., Ivarsson, S. A., & Lernmark, Å. (2010) · Wiley eBooks · doi:10.1002/9781444324808 · Cited by 75
Sosenko, J. M., Palmer, J. P., Greenbaum, C. J., Mahon, J., Cowie, C., Krischer, J. P., Chase, H. P., White, N. H., Buckingham, B., Herold, K. C., et al. (2007) · Diabetes Care · doi:10.2337/dc06-1615 · Cited by 60
Exploiting receptor biology for oral vaccination with biodegradable particulates
Foster, N. M., & Hirst, B. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.09.009 · Cited by 64
Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
Sosenko, J. M., Skyler, J. S., Mahon, J., Krischer, J. P., Beam, C. A., Boulware, D. C., Greenbaum, C. J., Rafkin, L. E., Cowie, C., Cuthbertson, D., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0641 · Cited by 61
Achenbach, P., Bonifacio, E. E., & Ziegler, A. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0035-y · Cited by 61
Anti-CD3 antibodies for type 1 diabetes: beyond expectations
Bach, J.-F. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60980-x · Cited by 59
Sosenko, J. M., Skyler, J. S., Mahon, J., Krischer, J. P., Greenbaum, C. J., Rafkin, L. E., Beam, C. A., Boulware, D. C., Matheson, D., Cuthbertson, D., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2359 · Cited by 60
Introduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 64
Tatović, D., McAteer, M. A., Barry, J., Barrientos, Á. G., Terradillos, K. R., Perera, I., Kochba, E., Levin, Y., Dul, M., Coulman, S. A., et al. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac002 · Cited by 66
Birth and coming of age of islet autoantibodies
Bonifacio, E. E., & Achenbach, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13360 · Cited by 66
Narendran, P., Estella, E., & Fourlanos, S. (2005) · QJM · doi:10.1093/qjmed/hci088 · Cited by 68
Triolo, T. M., Chase, H. P., Barker, J. M., & the DPT-1 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1872 · Cited by 55
Krishnamurthy, B., Mariana, L., Gellert, S. A., Colman, P. G., Harrison, L. C., Lew, A. M., Santamaria, P., Thomas, H. E., & Kay, T. W. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4458 · Cited by 56
Feldmann, M., & Maini, R. N. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39269 · Cited by 61
Lambert, P. F., & Bingley, P. J. (2002) · Medicine · doi:10.1383/medc.30.1.1.28264 · Cited by 75
Diet, Growth, and the Risk for Type 1 Diabetes in Childhood
Pundziūtė-Lyckå, A., Persson, L. Å., Cedermark, G., Roth, A. J., Nilsson, U., Westin, V., & Dahlquist, G. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2784 · Cited by 62
Mordes, J. P., Guberski, D. L., Leif, J., Woda, B. A., Flanagan, J. F., Greiner, D. L., Kislauskis, E., & Tirabassi, R. S. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2727 · Cited by 61
Michels, A. W., & Eisenbarth, G. S. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02091.x · Cited by 56
Sosenko, J. M., Skyler, J. S., Herold, K. C., Palmer, J. P., & Groups, T. T. 1. D. T. A. D. P. T. 1. S. (2012) · Diabetes · doi:10.2337/db11-1660 · Cited by 60
Metadata
- Authors
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Affiliations
- University of Miami (US)
- Corresponding author
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1685-1691
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W614574849
- Cited by
- 836
- References
- 30
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
- FWCI
- 28.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.